Kintor Pharmaceuticals
Kintor Pharmaceutical has recently announced the enrollment of its first participant in its “Pivotal Clinical Trial”. This is a Phase 2/3 trial in which men with androgenic alopecia will be treated with either vehicle control, 0.5%, or 1% topical for 24 weeks. The trial will be conducted in China, with 222 patients enrolled in each…
Read More
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read More
Published on: Oct 7, 2020 at 20:04
Read More
China Trial Enrolls 180 Patients To Complete Enrollment: Update (8/22/23) On August 22, 2023, Kintor Pharmaceutical announced the completion of patient enrollment in a phase 2 trial in China for GT20029. This means all of the patients needed to complete the study have been enrolled, and will undergo their dosing schedule over the next 12…
Read More
On May 11, 2023, Kintor Pharmaceutical of China announced results from their US phase 2 trial testing KX-826 aka pyrilutamide in males with androgenetic alopecia. Successful Phase 2 Trial For US KX-826 Trial As is the trend for Kintor Pharmaceutical’s AGA programs, today’s announcement included positive results in a human trial. This milestone will help…
Read More
The long awaited phase II results from Kintor’s KX-826 (pyrilutamide) study in males with androgenetic alopecia have surfaced online. KX-826 Phase 2 Results Presentation Several months ago in May, the 28th Annual Meeting of the Chinese Society of Dermatology was postponed from June to the beginning of September 2022. This was the acclaimed conference where…
Read More
Kintor Pharmaceutical of China brings us some timely good news today regarding its lead candidate drug KX-826 for the treatment of androgenetic alopecia. Phase 3 Will Be Soon A well respected company in the hair growth industry, Kintor Pharmaceutical, continues to outpace the competition. In a press release issued today, the company announced that KX-826…
Read More
US Male Phase 2 Pyrilutamide Trial Underway: Update (3/1/22) Consistent progress is the M.O. of Kintor Pharma. On March 1, 2022 it was announced that the first patients in a US phase 2 trial for males have received dosing. The four cohorts in the trial will receive topical dosing of either 2.5 mg pyrilutamide twice…
Read More
It’s always pleasing to learn of new companies who are developing drugs to treat hair loss. The more companies there are in the pipeline, the greater the chances are for success. Kintor Pharmaceuticals of China is the latest company to enter the global pharma market of alopecia treatments. Kintor Pharmaceuticals Pipeline There are two listed…
Read More